

Committee on Energy and Commerce  
U.S. House of Representatives  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: David A. Broecker		
2. Your Title: Founding CEO		
3. The Entity(ies) You are Representing: Indiana Biosciences Research Institute		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No X
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.  not applicable		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: \_\_\_\_\_

Date: NOVEMBER 14, 2017

# David Broecker

Experienced life sciences leader, innovator, and entrepreneur

DBroecker@indianabiosciences.org

---

## Summary

David is an experienced life sciences executive with a passion and track record for building organizations and creating value by advancing breakthrough innovation to the marketplace. He is the founding President and CEO of the Indiana Biosciences Research Institute in Indianapolis, IN – an independent, non-profit research organization dedicated to discovery science and applied research initially targeting diabetes, cardio-metabolic disease, and poor nutrition, inspired by the state's leading life sciences companies. David was President and CEO of Alkermes, a publicly traded biotechnology company, leading the organization through significant transformation with the launch of several new products, including Vivitrol - the only long acting treatment for alcohol and opiate dependence. As both an intra- and entrepreneur, he has led teams in a range of organizations, including multiple start-ups. David started his career at Eli Lilly and Company and over 15 years was responsible for supporting the development and commercialization of multiple pharmaceutical, medical device, and diagnostic products.

He currently serves on the boards of Zorion Medical, Inc., and Apexian Pharmaceuticals. He is on the advisory boards for AIT BioSciences and Embera. David is a trustee at Wabash College and member of Purdue Research Foundation board.

---

## Experience

### **Founder and Principal at Legacy BioSciences Consulting**

February 2013 - Present

Provide executive leadership, strategic consulting, and project management support to a limited number of highly innovative bio-pharmaceutical, medical device, and diagnostic companies. Development emphasis is on rapidly demonstrating proof-of-concept in clinical applications of high unmet medical need. Commercialization focus targets specialty markets. Current portfolio includes technologies targeting oncology, drug delivery, digital biomarkers, and addiction disorders.

### **Founder and Executive Chairman at Zorion Medical, Inc. at Zorion Medical, Inc.**

January 2011 - Present

Founded a breakthrough medical device company focused on next generation technology based on novel, absorbable, bio-alloy materials. Current focus is on developing intravascular devices targeting peripheral artery disease. Demonstrated proof-of-concept in multiple in-vitro and in-vivo models. Development activities underway to advance the first product application to clinical evaluation.

### **Founding President and CEO at Indiana Biosciences Research Institute**

March 2014 - September 2017 (3 years 7 months)

Led the formation of the IBRI, a non-profit, independent research institute focused on accelerating discovery and innovation in collaboration with academic, corporate, and public partners. Raised more than \$170 million and built the organization to launch research operations, attracting world-class entrepreneurial research talent to the Institute. Project portfolio includes programs targeting regenerative medicine for type 1 diabetes; applied data sciences including the development of digital health platforms; and single-cell bio-analytic capabilities focused on identifying novel biomarkers and diagnostics.

**President at Harlan Laboratories (now Envigo)**

January 2012 - February 2013 (1 year 2 months)

President of the global research models and services division with overall P+L accountability and responsibility for 1500 employees in 20 countries. Developed and began to execute a strategic growth plan based on the creation of new products and services, increased market share, and expansion into emerging markets. I left to pursue better growth opportunities in the bio-pharmaceutical and medical device industries.

**Founder and CEO at BioCritica**

January 2011 - December 2011 (1 year)

Founded BioCritica, a biopharmaceutical company focused on meeting the needs of critical care patients in the hospital market. Led the activities between Eli Lilly and Company and private investors (Care Capital/ Novaquest) to build a company to relaunch Xigris in the US market. Following negative clinical trial results, the company was closed.

**President and CEO at Alkermes at Alkermes**

April 2007 - September 2009 (2 years 6 months)

Led the strategic transformation of Alkermes from a partner-driven, drug delivery biotechnology company to a profitable, integrated biopharmaceutical company with the capabilities to develop and commercialize proprietary products. Successfully developed and launched two products - Risperdal Consta (schizophrenia) with JNJ and Vivitrol (alcohol and opiate dependence). Built and advanced a portfolio of early and late stage clinical assets and created a specialty sales and marketing organization to commercialize products.

**President and Chief Operating Officer at Alkermes at Alkermes**

February 2001 - March 2007 (6 years 2 months)

**Various Positions at Eli Lilly and Company at Eli Lilly and Company**

August 1985 - January 2001 (15 years 6 months)

High potential leader with a variety of experiences across engineering, manufacturing and operations, sales and marketing, strategic planning, new product development, and business development. Worked across pharmaceutical and medical device (Advanced Cardiovascular Systems/Guidant) divisions. Strategic commercial leadership for anti-infectives (Ceclor) and CNS (Prozac and Zyprexa) products. Operations GM in Germany and Ireland.

## Education

### **Massachusetts Institute of Technology**

MS, Chemical Engineering, 1983 - 1985

**Activities and Societies:** MIT Practice school assignments with GE and Bethlehem Steel

### **University of Chicago**

Master of Business Administration (MBA), Finance and Marketing, 1987 - 1989

**Activities and Societies:** Summer brand management intern at Procter & Gamble

### **Wabash College**

Bachelor of Arts (BA), Chemistry, Physics, Mathematics, 1979 - 1983

**Activities and Societies:** Summa cum laude, Phi Beta Kappa, All-American football (QB)

---